深部脑磁刺激对帕金森病模型大鼠运动症状治疗的安全性评价

doi:10.3969/j.issn.1006-7795.2017.02.020

首都医科大学学报 ›› 2017, Vol. 38 ›› Issue (2): 260-267.doi: 10.3969/j.issn.1006-7795.2017.02.020

深部脑磁刺激对帕金森病模型大鼠运动症状治疗的安全性评价

刘俊华^1,2,3, 王勇^2,3,4, 王颜颜^1,2,3, 王晓民^1,2,3

1. 首都医科大学基础医学院神经生物学系, 北京 100069;
2. 教育部神经变性病重点实验室, 北京 100069;
3. 北京脑重大疾病研究院, 北京 100069;
4. 首都医科大学基础医学院生理学与病理生理学系, 北京 100069

收稿日期:2017-03-15 出版日期:2017-03-21 发布日期:2017-04-17
通讯作者: 王晓民,E-mail:xmwang@ccmu.edu.cn E-mail:xmwang@ccmu.edu.cn
基金资助:
国家重点基础研究发展计划（“973”计划）（2011CB504100），北京市自然科学基金项目（7082008），北京市科学技术委员会专项资助（Z161100002616007），北京市属高等学校创新团队建设与教师职业发展计划项目（IDHT20140514）

Safety evaluation during deep-brain magnetic stimulation (DMS)treating motor symptoms in Parkinsonian rats

Liu Junhua^1,2,3, Wang Yong^2,3,4, Wang Yanyan^1,2,3, Wang Xiaomin^1,2,3

1. Department of Neurobiology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, China;
2. Key Laboratory of Neurodegenerative Disorders of the Ministry of Education, Beijing 100069, China;
3. Beijing Institute for Brain Disorders, Beijing 100069, China;
4. Department of Physiology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, China

Received:2017-03-15 Online:2017-03-21 Published:2017-04-17
Supported by:
This study was supported by National Basic Research Program of China (“973” Fundamental Research) (2011CB504100), Natural Science Foundation of Beijing (7082008),Beijing Municipal Science & Technology Commission (Z161100002616007),The Project of Construction of Innovative Teams and Teacher Career Development for Universities and Colleges Under Beijing Municipality (IDHT20140514)

摘要/Abstract

摘要： 目的评估深部脑磁刺激（deep-brain magnetic stimulation，DMS）对单侧帕金森病（Parkinson's disease，PD）模型大鼠运动障碍的治疗作用及DMS治疗的安全性。方法立体定位注射六羟基多巴胺（6-hydroxydopamine，6-OHDA）于大鼠右侧纹状体制备单侧帕金森病模型，假手术对照组（Sham组）依据同样方法注射0.9%（质量分数）氯化钠注射液。利用阿扑吗啡筛选模型后，造模成功的动物采用均衡随机化分组的方式分为模型对照组（Model组）、δ节律DMS治疗组（DMS-δ组）、γ节律DMS治疗组（DMS-γ组），其中两种DMS治疗组行每天40 min、持续4周的DMS治疗。通过碰壁实验检测大鼠运动行为，通过大鼠体质量的测定、外周血淋巴细胞的分类及计数、主要组织器官的苏木精-伊红（Hematoxylin-Eosin staining，HE）染色评价DMS治疗的安全性。结果 1检测大鼠运动行为显示，DMS-γ治疗组损伤侧的肢体利用率显著高于Model组，差异具有统计学意义（P<0.05），而DMS-δ组相较于Model组差异无统计学意义（P>0.05）。2Sham组、Model组、DMS-δ组、DMS-γ组大鼠体质量差异均无统计学意义（P>0.05）。3Sham组、Model组、DMS-δ组、DMS-γ组大鼠外周血总淋巴细胞与T细胞的数量和比例差异均无统计学意义（P>0.05）。DMS-δ组大鼠的自然杀伤（natural killer，NK）细胞数量和比例相较于Model组有显著改善。4HE染色显示，DMS对大鼠主要器官包括心、肝、脾、肺、肾、胃、小肠、睾丸均未造成明显的组织病理变化。结论 DMS-γ治疗可改善PD大鼠双侧肢体不对称性运动障碍，且DMS对PD大鼠运动行为的治疗中无明显不良反应，表明DMS在对PD大鼠运动症状的治疗中具有很好的安全性。

关键词: 帕金森病, 深部脑磁刺激, 运动行为学, 不良反应, 安全性

Abstract: Objective To explore the security via DMS to treat motor symptoms in hemi-parkinsonian rats.Methods Rats were injected with 6-hydroxydopamine (6-OHDA) into right striatum to establish unilateral parkinsonian model. Sham group received the same volume of normal saline by the same procedure. After screened via apomorphine, the successful parkinsonian rats were randomly grouped into model, δ rhythm DMS treatment (DMS-δ) and γ rhythm DMS treatment (DMS-γ). Among each DMS treatment group, 40 minutes trains of DMS were administered daily for 4 weeks. Cylinder tests were conducted to detect motor outcomes. Body weight determination, peripheral blood lymphocytes classification & counting, HE staining were executed to evaluate the security of DMS. Results 1The lesioned side forelimb usage ratio in Sham and DMS-γ groups were significantly higher than that in Model group. 2There was no significant difference of body weight between each group, indicating that DMS had no significant effects on body weight. 3There was no significant difference of the number and percentage of total lymphocytes & T cells between each group, while the natural killer (NK) cells number and percentage in DMS-δ group were significantly higher than that in Model group. 4Results of HE staining for major organs showed no significant histopathological change. Conclusion DMS-γ treatment alleviated bilateral limb asymmetry in PD rats. Meanwhile, DMS treatment showed no significant side effects, indicating that DMS showed satisfactory security in the treatment of motor symptoms in PD rats.

Key words: Parkinson's disease, deep-brain magnetic stimulation, motor behavior, side effects, safety

中图分类号:

R742.5

刘俊华, 王勇, 王颜颜, 王晓民. 深部脑磁刺激对帕金森病模型大鼠运动症状治疗的安全性评价[J]. 首都医科大学学报, 2017, 38(2): 260-267.

Liu Junhua, Wang Yong, Wang Yanyan, Wang Xiaomin. Safety evaluation during deep-brain magnetic stimulation (DMS)treating motor symptoms in Parkinsonian rats[J]. Journal of Capital Medical University, 2017, 38(2): 260-267.

参考文献

[1] Dauer W, Przedborski S. Parkinson's disease: mechanisms and models[J]. Neuron, 2003,39(6):889-909.
[2] Braak H, Del Tredici K. Cortico-basal ganglia-cortical circuitry in Parkinson's disease reconsidered[J]. Exp Neurol,2008, 212(1):226-229.
[3] Obeso J A, Rodriguez-Oroz M C, Goetz C G, et al. Missing pieces in the Parkinson's disease puzzle[J]. Nat Med,2010,16(6):653-661.
[4] Moldovan A S, Groiss S J, Elben S, et al. The treatment of parkinson's disease with deep brain stimulation: current issues[J]. Neural Regen Res,2015,10(7):1018-1022.
[5] Baizabal-Carvallo J F, Jankovic J. Movement disorders induced by deep brain stimulation[J]. Parkinsonism Relat Disord,2016(25):1-9.
[6] Fitzgerald P B, Daskalakis Z J. The effects of repetitive transcranial magnetic stimulation in the treatment of depression[J]. Expert Rev Med Devices,2011,8(1):85-95.
[7] Bentwich J, Dobronevsky E, Aichenbaum S, et al. Beneficial effect of repetitive transcranial magnetic stimulation combined with cognitive training for the treatment of Alzheimer's disease: a proof of concept study[J]. J Neural Transm (Vienna),2011,118(3):463-471.
[8] Deng Z D, Lisanby S H, Peterchev A V. Electric field depth-focality tradeoff in transcranial magnetic stimulation: simulation comparison of 50 coil designs[J]. Brain Stimul,2013,6(1):1-13.
[9] Chen R, Gerloff C, Classen J, et al. Safety of different inter-train intervals for repetitive transcranial magnetic stimulation and recommendations for safe ranges of stimulation parameters[J]. Electroencephalogr Clin Neurophysiol,1997,105(6):415-421.
[10] Wassermann E M. Risk and safety of repetitive transcranial magnetic stimulation: report and suggested guidelines from the International Workshop on the Safety of Repetitive Transcranial Magnetic Stimulation, June 5-7, 1996[J]. Electroencephalogr Clin Neurophysiol,1998,108(1):1-16.
[11] Zhang Y, Mao R R, Chen Z F, et al. Deep-brain magnetic stimulation promotes adult hippocampal neurogenesis and alleviates stress-related behaviors in mouse models for neuropsychiatric disorders[J]. Mol Brain,2014(7):11.
[12] Blandini F, Armentero M T. Animal models of Parkinson's disease[J]. FEBS J,2012,279(7):1156-1166.
[13] Ma Y, Zhan M, OuYang L, et al. The effects of unilateral 6-OHDA lesion in medial forebrain bundle on the motor, cognitive dysfunctions and vulnerability of different striatal interneuron types in rats[J]. Behav Brain Res,2014(266):37-45.
[14] Iderberg H, McCreary A C, Varney M A, et al. NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat[J]. Exp Neurol,2015,271:335-350.
[15] Domecq J P, Prutsky G, Leppin A, et al. Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis[J]. J Clin Endocrinol Metab,2015,100(2):363-370.
[16] Matsunaga S, Osawa T, Geshi M, et al. Effect of a single intrauterine administration of recombinant bovine interferon-T on day 7 of the estrous cycle on the luteal phase length and blood profile in dairy cows[J]. Res Vet Sci,2012,93(1):381-385.
[17] Zhou S, Zhang B, Liu X, et al. A new natural angelica polysaccharide based colon-specific drug delivery system[J]. J Pharm Sci,2009,98(12):4756-4768.
[18] de Alencar N M, da Silveira Bitencourt F, de Figueiredo I S, et al. Side-Effects of Irinotecan (CPT-11), the Clinically Used Drug for Colon Cancer Therapy, Are Eliminated in Experimental Animals Treated with Latex Proteins from Calotropis procera (Apocynaceae)[J]. Phytother Res,2017,31(2):312-320.
[19] Cooper M D. The early history of B cells[J]. Nat Rev Immunol,2015,15(3):191-197.
[20] Popko K, Gorska E. The role of natural killer cells in pathogenesis of autoimmune diseases[J]. Cent Eur J Immunol,2015,40(4):470-476.
[21] Spitaels J, Roose K, Saelens X. Influenza and memory T cells: how to awake the force[J]. Vaccines (Basel),2016,4(4)Pii: E33.
[22] Shrestha R, Shakya Shrestha S, Millingtona O, et al. Immune responses in neurodegenerative diseases[J]. Kathmandu Univ Med J (KUMJ),2014,12(45):67-76.

深部脑磁刺激对帕金森病模型大鼠运动症状治疗的安全性评价

Safety evaluation during deep-brain magnetic stimulation (DMS)treating motor symptoms in Parkinsonian rats

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	罗炯, 孙丛丛, 潘伟刚, 王丹, 史晓宁, 王茜, 金文青, 梁立荣, 杨春林, 马辛, 任艳萍. 经颅交流电刺激联合抗抑郁药对抑郁发作的疗效及安全性[J]. 首都医科大学学报, 2022, 43(2): 244-248.
[2]	李莉, 刘超猛, 任艳萍, 杨春林, 马辛. 改良电休克治疗首发精神分裂症的研究进展[J]. 首都医科大学学报, 2022, 43(2): 249-253.
[3]	何振, 刘娟, 冀明, 李鹏, 张澍田. 内镜下黏膜剥离术治疗累及肛门齿状线直肠病变的临床效果评价[J]. 首都医科大学学报, 2022, 43(1): 38-41.
[4]	粟文婷, 於佳楠, 贾军, 王晓民. 电针对帕金森病模型小鼠纹状体背侧的c-Fos表达的选择性调节[J]. 首都医科大学学报, 2021, 42(6): 986-992.
[5]	高歌, 查旭, 刘伟进, 杨慧. 129位丝氨酸磷酸化α-突触核蛋白DELFIA检测方法的建立及初步应用[J]. 首都医科大学学报, 2021, 42(5): 776-782.
[6]	程姣姣, 阮祥燕, 杜娟, 金凤羽, 李扬璐, 谷牧青. 卵巢组织冻存移植安全性的研究进展[J]. 首都医科大学学报, 2021, 42(4): 505-510.
[7]	王梦月, 赵鑫, 曹枭, 王可, 贾军. 帕金森病小鼠模型自主活动状态下的运动启动分析[J]. 首都医科大学学报, 2021, 42(4): 553-558.
[8]	袁惠莉, 宫晓丽, 范征, 梁志刚, 王晓民. 远志皂苷对脂多糖诱导的帕金森病模型大鼠的作用及机制研究[J]. 首都医科大学学报, 2020, 41(6): 914-922.
[9]	宋启晗, 李旭冉, 李昕, 杨巍巍, 李伟, 于顺. 不同亚型的帕金森病及多系统萎缩患者血浆α-突触核蛋白寡聚体浓度分析[J]. 首都医科大学学报, 2020, 41(2): 212-216.
[10]	丁晖, 蔡彦宁, 陈彪. 灵芝提取物对MPP⁺诱导的Neuro-2a细胞自噬的影响[J]. 首都医科大学学报, 2019, 40(4): 596-601.
[11]	张辉, 马惠清, 王森茂, 王晓娟. 银杏叶提取物对帕金森病模型大鼠脑内神经炎性反应的影响[J]. 首都医科大学学报, 2019, 40(3): 439-442.
[12]	李杰, 谢秀娟, 宋炜, 潘维花, 杨巍巍, 于顺. 帕金森病患者血浆增强α-突触核蛋白细胞毒性及其机制研究[J]. 首都医科大学学报, 2019, 40(2): 244-250.
[13]	吕霞丽, 李自慧, 潘丽萍, 贾红彦, 张宗德, 刘洋. 乙酰丙酸－十二烷基硫酸钠对结核分枝杆菌的杀灭作用及其安全性毒理学评价[J]. 首都医科大学学报, 2018, 39(6): 894-899.
[14]	刘梦茹, 宫晓丽, 王乐, 刘玚, 张婷, 王晓民. 脂多糖对肠道α-突触核蛋白表达的影响[J]. 首都医科大学学报, 2018, 39(4): 557-562.
[15]	常忠莲, 盛晓滨, 石新兰, 韦薇. 桂枝茯苓汤辨证加味对晚期宫颈癌化学药物治疗患者的增效减毒作用[J]. 首都医科大学学报, 2018, 39(4): 596-601.